17682-1-AP

antibody from Proteintech Group

Targeting: AHNAK2 C14orf78

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

17682-1-AP

Provider

Proteintech Group

Product name

AHNAK2 antibody

Antibody type

Polyclonal

Description

KD/KO validated AHNAK2 antibody (Cat. #17682-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC,ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

AHNAK2 exacerbates the malignant phenotype of gastric cancer through activation of the Wnt/β-catenin signaling pathway.

Liu X, Ma L, Wang R, Liu Q
Discover oncology 2026 Feb 8;17(1)

---

The genetic landscape of primary malignant melanoma of the cervix using integrated bioinformatics analysis and whole-exome sequencing.

Zhou J, Xu T, Chen C, Ping Y
Frontiers in oncology 2025;15:1597153

---

AHNAK2 Promotes the Progression of Pancreatic Ductal Adenocarcinoma by Maintaining the Stability of c-MET.

Chen Z, Miao P, Lin H, Lu Y
Cancer management and research 2024;16:431-444

---

Clinical-proteomic classification and precision treatment strategy of chordoma.

Yin H, Hu J, Gao J, Su T, Jin J, Jiang C, Yin W, Xu X, Chang Z, Sun W, Cai Z, Zhou W, Wang P, Lin J, Song D, Meng T
Cell reports. Medicine 2024 Oct 15;5(10):101757

---

Identification of gemcitabine resistance-related AHNAK2 gene associated with prognosis and immune infiltration in pancreatic cancer.

Ou G, Tian Z, Su M, Yu M, Gong J, Chen Y
Heliyon 2024 Jul 15;10(13):e33687

---

Inhibition of AHNAK nucleoprotein 2 alleviates pulmonary fibrosis by downregulating the TGF-β1/Smad3 signaling pathway.

Zhu D, Zhang Q, Li Q, Wang G, Guo Z
The journal of gene medicine 2022 Sep;24(9):e3442

---

The AHNAK induces increased IL-6 production in CD4+ T cells and serves as a potential diagnostic biomarker for recurrent pregnancy loss.

Li L, Liu Y, Feng T, Zhou W, Wang Y, Li H
Clinical and experimental immunology 2022 Sep 29;209(3):291-304

---

AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.

Zheng L, Li S, Zheng X, Guo R, Qu W
International immunopharmacology 2021 Jan;90:107185

---

Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.

Zheng M, Liu J, Bian T, Liu L, Sun H, Zhou H, Zhao C, Yang Z, Shi J, Liu Y
International immunopharmacology 2021 Jan;90:107134

---

AHNAK2 Promotes Migration, Invasion, and Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cells via the TGF-β/Smad3 Pathway.

Liu G, Guo Z, Zhang Q, Liu Z, Zhu D
OncoTargets and therapy 2020;13:12893-12903

---

Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer.

Ohmura H, Ito M, Uchino K, Okada C, Tanishima S, Yamada Y, Momosaki S, Komoda M, Kuwayama M, Yamaguchi K, Okumura Y, Nakano M, Tsuchihashi K, Isobe T, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E
FEBS open bio 2020 Jan;10(1):147-157